Close

elotuzumab (TAB-743)

DESCRIPTION CATALOG # SIZE PRICE
Anti-SLAMF7 Therapeutic Antibody TAB-743 1mg Please Inquiry

PRODUCT INFORMATION

  • Product Overview
  • Recombinant humanized antibody expressed in CHO binding to human SLAMF7/CD319. Elotuzumab is a humanized monoclonal antibody which is under phase III clinical investigation in relapsed multiple myeloma.
  • Target
  • SLAMF7/CD319
  • Type
  • IgG1 - kappa
  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Species Reactivity
  • Human
  • Expression Host
  • CHO
  • Applications
  • Suitable for use in FuncS, IF, Neut, ELISA, FC, IP, IHC and most other immunological methods.
  • CAS
  • 915296-00-3
  • Predicted N terminal
  • EVQLVESG
  • Molecular Weight
  • 145.5 kDa
  • Purity
  • >95.0%, determined by analysis by RP-HPLC & analysis by SDS-PAGE.
  • Size
  • 1mg
  • Storage
  • Store at -20°C. Avoid multiple freeze/thaw cycles.

BACKGROUND

  • Introduction
  • Elotuzumab (also known as HuLuc63) is a humanized monoclonal antibody which is under phase III clinical investigation in relapsed multiple myeloma.
  • Antigen Description
  • SLAM family member 7 is a protein that in humans is encoded by the SLAMF7 gene.
  • Function
  • receptor activity;
  • Synonyms
  • SLAMF7; SLAM family member 7; 19A; CD319; CRACC; CS1; protein 19A; CD2 subset 1; 19A24 protein; membrane protein FOAP-12; CD2-like receptor activating cytotoxic cells; CD2-like receptor-activating cytotoxic cells; novel LY9 (lymphocyte antigen 9) like protein;

Related Products

Online Inquiry

Verification code
Click image to refresh the verification code.

CONTACT US

45-1 Ramsey Road, Shirley, NY 11967, USA
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us